{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:51:09Z","timestamp":1787611869245,"version":"build-2736575974"},"reference-count":57,"publisher":"FapUNIFESP (SciELO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:p>The objective this study was to summarize long-term risks associated with bisphosphonate therapy. Search of relevant medical publications for data from clinical trials, trial extensions, observational studies and post-marketing reports. Trial extensions and modifications did not reveal significant long-term safety issues. Observational data suggest at least as many benefits as risks. Post-marketing reports of musculoskeletal pain, osteonecrosis of the jaw and atypical femur fractures have been widely circulated in the lay press. Most focus on long-terms risks has been on osteonecrosis of the jaw and atypical femur fractures which occur in patients who have not received bisphosphonate therapy but may be more frequent (though still uncommon) in patients who have been on treatment for 5 years or longer. Lower-risk patients may be able to stop treatment after 3-5 years for a \u201cdrug holiday,\u201d which mitigates these long-term risks; for higher risk patients, therapy through 6-10 years appears to be advisable and offers more benefits than risks.<\/jats:p>","DOI":"10.1590\/0004-2730000003308","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T14:56:35Z","timestamp":1408546595000},"page":"523-529","source":"Crossref","is-referenced-by-count":21,"title":["Long-term risks of bisphosphonate therapy"],"prefix":"10.1590","volume":"58","author":[{"given":"Nelson B.","family":"Watts","sequence":"first","affiliation":[{"name":"Mercy Health Osteoporosis and Bone Health Services,  United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell RGG","year":"1999","journal-title":"Bone"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years? experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone HG","year":"2004","journal-title":"New Engl J Med"},{"issue":"24","key":"ref3","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black DM","year":"2006","journal-title":"JAMA"},{"issue":"9041","key":"ref4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black DM","year":"1996","journal-title":"Lancet"},{"issue":"14","key":"ref5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris ST","year":"1999","journal-title":"JAMA"},{"issue":"18","key":"ref6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of osteoporosis","volume":"356","author":"Black DM","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","article-title":"The acute phase response after bisphosphonate administration","volume":"41","author":"Adami S","year":"1987","journal-title":"Calcif Tissue Int"},{"issue":"8653","key":"ref8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(89)90277-8","article-title":"Side-effects of pamidronate","volume":"2","author":"Gallacher SJ","year":"1989","journal-title":"Lancet"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","article-title":"Comparative tolerability of drug therapies for hypercalcaemia of malignancy","volume":"21","author":"Zojer N","year":"1999","journal-title":"Drug Saf"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4158\/EP.12.1.48","article-title":"Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature","volume":"12","author":"Maalouf NM","year":"2006","journal-title":"Endocr Pract"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller PD","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal SA","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts NB","year":"2008","journal-title":"Osteoporos Int"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstr\u00f6m DD","year":"2004","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black DM","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"3","key":"ref16","first-page":"346","article-title":"Alendronate and risedronate: reports of severe bone, joint, and muscle pain","volume":"165","author":"Wysowski DK","year":"2005","journal-title":"Arch Intern Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles KW","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-200932030-00004","article-title":"Bisphosphonates and atrial fibrillation: systematic review and meta-analysis","volume":"32","author":"Loke YK","year":"2009","journal-title":"Drug Saf"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004720","article-title":"Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis","volume":"4","author":"Grosso A","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00198-011-1546-9","article-title":"Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials","volume":"23","author":"Barrett-Connor E","year":"2012","journal-title":"Osteoporos Int"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00198-011-1608-z","article-title":"Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis","volume":"23","author":"Rhee CW","year":"2012","journal-title":"Osteoporos Int"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc0808738","article-title":"Reports of esophageal cancer with oral bisphosphonate use. (letter)","volume":"360","author":"Wysowski DK.","year":"2009","journal-title":"N Engl J Med"},{"issue":"1791","key":"ref23","article-title":"More on reports of esophageal cancer with oral bisphosphonate use (letter)","volume":"360","author":"Siris ES","year":"2009","journal-title":"N Engl J Med"},{"key":"ref24","first-page":"1790","article-title":"More on reports of esophageal cancer with oral bisphosphonate use (letter)","volume":"360","author":"Shaheen NJ.","year":"2009","journal-title":"N Engl J Med"},{"issue":"1789","key":"ref25","article-title":"More on reports of esophageal cancer with oral bisphosphonate use (letter)","volume":"360","author":"Abrahamsen B","year":"2009","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMc096026","article-title":"More on reports of esophageal cancer with oral bisphosphonate use (letter)","volume":"360","author":"Solomon DH","year":"2009","journal-title":"N Engl J Med"},{"key":"ref27","article-title":"More on reports of esophageal cancer with oral bisphosphonate use (letter)","volume":"360","author":"Hofbauer LC","year":"2009","journal-title":"N Engl J Med"},{"key":"ref28","article-title":"More on reports of esophageal cancer with oral bisphosphonate use (letter)","volume":"360","author":"Robins HI","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","article-title":"Exposure to oral bisphosphonates and risk of esophageal cancer","volume":"304","author":"Cardwell CR","year":"2010","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4444","article-title":"Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort","volume":"341","author":"Green J","year":"2010","journal-title":"BMJ"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic (letter)","volume":"61","author":"Marx RE.","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero SL","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo S-B","year":"2006","journal-title":"Ann Intern Med"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla S","year":"2007","journal-title":"J Bone Miner Res"},{"key":"ref35","article-title":"Bisphosphonate-associated osteonecrosis of the jaw","volume":"335","author":"Triester N","year":"2006","journal-title":"N Engl J Med"},{"issue":"22","key":"ref36","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw--do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian JP.","year":"2006","journal-title":"N Engl J Med"},{"key":"ref37","article-title":"Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial (abstract)","volume":"21","author":"Black DM","year":"2006","journal-title":"J Bone Miner Res"},{"key":"ref38","series-title":"2006 Annual Report IMS HEALTh","year":"2006"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad F","year":"2012","journal-title":"Ann Oncol"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein JW","year":"2011","journal-title":"J Am Dent Assoc"},{"issue":"3","key":"ref41","first-page":"349","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"Goh SK","year":"2007","journal-title":"J Bone Joint Surg Br"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use","volume":"22","author":"Neviaser AS","year":"2008","journal-title":"J Orthop Trauma"},{"issue":"8","key":"ref43","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study","volume":"20","author":"Lenart BA","year":"2009","journal-title":"Osteoporos Int"},{"issue":"8","key":"ref44","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.2011.190","article-title":"Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women","volume":"305","author":"Park-Wyllie LY","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00223-011-9463-7","article-title":"Use of bisphosphonates and risk of breast cancer","volume":"88","author":"Vestergaard P","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"ref46","first-page":"343","article-title":"Oral bisphosphonate use associated with a decreased risk of breast cancer","volume":"60","author":"Dreyfuss JH.","year":"2010","journal-title":"Cancer"},{"issue":"22","key":"ref47","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","article-title":"Oral bisphosphonate use and breast cancer incidence in postmenopausal women","volume":"28","author":"Chlebowski RT","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"ref48","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","article-title":"Use of bisphosphonates and risk of postmenopausal breast cancer","volume":"28","author":"Rennert G","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref49","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.2010.33.7485","article-title":"Use of bisphosphonates and reduced risk of colorectal cancer","volume":"29","author":"Rennert G","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jbmr.1481","article-title":"Esophageal and gastric cancer incidence and mortality in alendronate users","volume":"27","author":"Abrahamsen B","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/rtph.2002.1550","article-title":"Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study","volume":"35","author":"Steinbuch M","year":"2002","journal-title":"Regul Toxicol Pharmacol"},{"issue":"5","key":"ref52","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.1792","article-title":"Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis","volume":"28","author":"Wolfe F","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"1","key":"ref53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-012-2176-6","article-title":"The effect of treatments for osteoporosis on mortality","volume":"24","author":"Grey A","year":"2013","journal-title":"Osteoporos Int"},{"key":"ref54","first-page":"S16","article-title":"Efficacy of continued alendronate for fractures in women without prevalent vertebral fracture: The FLEX trial (abstract)","volume":"22","author":"Schwartz AV","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"22","key":"ref55","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis--where do we go from here?","volume":"366","author":"Whitaker M","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"ref56","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts NB","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"ref57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00223-009-9263-5","article-title":"Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series","volume":"85","author":"Armamento-Villareal R","year":"2009","journal-title":"Calcif Tissue Int"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v58n5\/0004-2730-abem-58-5-0523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T16:57:52Z","timestamp":1495904272000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302014000500523&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0004-27302014000500523"],"URL":"https:\/\/doi.org\/10.1590\/0004-2730000003308","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}